8-K current report · filed Oct 22, 2026

Arbutus Biopharma Corp (ABUS) 8-K Current Report: October 22, 2026

Item 8.01Item EX-99.1ABUS overview

Short answer

Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA clinical hold lifted for AB-101, Arbutus’s oral PD-L1 inhibitor.

Arbutus Biopharma Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA clinical hold lifted for AB-101, Arbutus’s oral PD-L1 inhibitor
  • Clinical development can resume, reducing a key regulatory obstacle
  • Press release dated October 22, 2026, contains additional program details

Item EX-99.1 · Exhibit EX-99.1

  • FDA clinical hold lifted for AB-101, restoring U.S. clinical development eligibility
  • AB-101 Phase 1a/1b data showed generally good tolerability and high receptor occupancy in seven cHBV patients
  • Two cHBV patients showed hepatitis B surface antigen decline at the 30mg dose
  • Arbutus evaluating next development steps, with additional trials and funding needs remaining uncertain

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Arbutus Biopharma Corp 8-K filings

Get the next ABUS 8-K as it lands

Follow ABUS for push alerts, or ask the research agent what this filing means.